Last updated: September 8, 2026
ENGERIX-B is a recombinant hepatitis B vaccine marketed by GSK. Its commercial profile is mature and volume-driven rather than exclusivity-driven. The product operates in a competitive vaccine market with low direct patent protection, significant manufacturing and regulatory barriers, and demand supported by universal infant immunization, adult risk-based vaccination, healthcare-worker requirements, and expanded U.S. adult vaccination recommendations.
GSK does not disclose ENGERIX-B revenue as a separate product line. Its financial contribution is embedded within the company’s broader vaccines portfolio, which is dominated by products such as Shingrix, Arexvy, Boostrix, and specialty vaccines. ENGERIX-B therefore has strategic value as part of GSK’s hepatitis B and combination-vaccine franchise, but its standalone revenue trajectory cannot be calculated from public company reporting.
What is ENGERIX-B and how is it used?
ENGERIX-B contains recombinant hepatitis B surface antigen, or HBsAg, produced using genetically engineered yeast cells. It is indicated for active immunization against infection caused by hepatitis B virus.
The U.S. product is approved for use in infants, children, adolescents, and adults. It is administered in age- and risk-dependent schedules, generally as a two-dose or three-dose series. The vaccine is used in routine pediatric immunization, occupational vaccination, travel medicine, dialysis populations, and other at-risk groups. (U.S. Food and Drug Administration [FDA], 2024a)
ENGERIX-B dosage and delivery formats
| Population or use |
Typical schedule context |
Commercial implication |
| Infants |
Multi-dose pediatric series beginning at birth |
Supported by universal childhood immunization |
| Children and adolescents |
Age-based series |
Public-sector and routine pediatric demand |
| Adults |
Two-dose or three-dose schedules depending on product and use |
Exposed to competition from Heplisav-B and combination products |
| Healthcare workers and high-risk adults |
Series completion often required |
Institutional and occupational-health demand |
| Dialysis patients |
Higher-dose or specialized dosing requirements |
Smaller but medically important segment |
| International and travel use |
Risk-based vaccination |
Private-market and travel-clinic demand |
ENGERIX-B is also relevant to GSK’s broader hepatitis B franchise through combination vaccines, including Twinrix, which combines hepatitis A and hepatitis B antigens for adults, and pediatric combination products that include hepatitis B antigen.
What is the market size and competitive landscape for ENGERIX-B?
The hepatitis B vaccine market is fragmented by age group, public procurement, payer channel, and formulation. In the United States, demand is shaped by the Centers for Disease Control and Prevention’s recommendation that all adults ages 19 through 59 receive hepatitis B vaccination, with vaccination also recommended for adults 60 and older with risk factors or based on patient or clinician preference. (Centers for Disease Control and Prevention [CDC], 2024)
The principal competitive products include:
| Product |
Company |
Positioning |
| ENGERIX-B |
GSK |
Established recombinant hepatitis B vaccine for pediatric and adult use |
| Recombivax HB |
Merck |
Established recombinant hepatitis B vaccine |
| Heplisav-B |
Dynavax |
Two-dose adult vaccine using a CpG 1018 adjuvant |
| Twinrix |
GSK |
Combined hepatitis A and hepatitis B vaccine for adults |
| Vaxelis |
Mylan/Viatris and Sanofi |
Six-component pediatric combination vaccine containing hepatitis B antigen |
| Pediarix |
GSK |
Five-component pediatric combination vaccine containing hepatitis B antigen |
| Hexaxim and other hexavalent vaccines |
Multiple non-U.S. suppliers |
Important in international pediatric markets |
How does ENGERIX-B compare with Heplisav-B?
Heplisav-B is the main differentiated adult competitor in the U.S. market. Its two-dose schedule can reduce the time required to complete vaccination compared with traditional three-dose schedules. ENGERIX-B has a longer commercial history, broad pediatric and adult labeling, established procurement relationships, and extensive global distribution.
The competitive comparison is therefore segmented:
- ENGERIX-B has greater relevance in pediatric vaccination and established institutional channels.
- Heplisav-B has a schedule advantage in adult vaccination.
- Recombivax HB is a direct legacy competitor with similar recombinant-vaccine positioning.
- Combination vaccines compete for pediatric doses by reducing the number of injections required.
- Public-sector contracts can shift market share based on price, supply reliability, and inclusion in national immunization programs.
What is the financial trajectory of ENGERIX-B?
GSK does not publish ENGERIX-B net sales separately in its annual reports. The product is included in broader vaccines reporting, preventing a reliable standalone revenue series or margin estimate.
GSK’s vaccine segment has been reshaped by high-growth respiratory and shingles products. Shingrix and Arexvy account for a substantial share of the company’s vaccine revenue and growth commentary, while mature products such as ENGERIX-B are less visible in reported portfolio metrics. (GSK plc, 2024)
Financial trajectory drivers
| Driver |
Effect on ENGERIX-B |
| Routine infant vaccination |
Provides recurring baseline demand |
| Adult vaccination recommendation expansion |
Supports incremental U.S. demand |
| Heplisav-B adoption |
Creates share and pricing pressure in adults |
| Combination-vaccine substitution |
Can reduce use of standalone pediatric doses |
| Government tenders |
Pressure on price but support volume |
| Manufacturing costs |
Relevant because vaccine margins depend on yield, capacity, and cold-chain execution |
| GSK portfolio allocation |
May favor higher-growth products over mature standalone vaccines |
| Supply continuity |
A strong commercial asset in a procurement-driven market |
ENGERIX-B is likely a stable or mature revenue contributor rather than a high-growth product. Unit demand can expand when vaccination recommendations broaden, but price growth is constrained by government purchasing, competing products, and the availability of combination vaccines.
When does ENGERIX-B lose exclusivity?
ENGERIX-B does not have a conventional near-term small-molecule patent cliff. The product was first approved in the United States in the late 1980s, and any original composition, platform, or formulation patents that supported its initial launch would generally have expired or lost practical commercial relevance.
The relevant commercial distinction is between patent expiry and market entry. A competitor cannot enter simply because an old patent has expired. It must obtain its own biologics license, demonstrate product quality and manufacturing consistency, and satisfy FDA requirements for safety, immunogenicity, and lot release.
ENGERIX-B exclusivity profile
| Exclusivity category |
Current relevance |
| Small-molecule Orange Book patents |
Generally not applicable |
| Biologic reference-product exclusivity |
Historical protection is no longer a practical barrier |
| Pediatric exclusivity |
Any original pediatric extension is long expired |
| Orphan exclusivity |
Not applicable |
| Vaccine platform patents |
Potentially relevant only to specific manufacturing or formulation technologies |
| Manufacturing know-how |
Remains commercially important even after patent expiry |
| Regulatory approval |
Still required for every competing vaccine |
What is the Orange Book status of ENGERIX-B?
ENGERIX-B is licensed as a biologic under a Biologics License Application, or BLA, rather than approved as a conventional small-molecule drug under an NDA. Vaccines licensed under the Public Health Service Act generally are not assessed through the conventional Orange Book patent-listing framework used for prescription drugs.
As a result, the principal U.S. regulatory references are the FDA biologics license, prescribing information, product labeling, manufacturing controls, and the Purple Book framework where applicable. The absence of a conventional Orange Book listing does not eliminate regulatory barriers or protect against manufacturing competition. It means that patent certification and Paragraph IV litigation are not the central entry mechanisms for this vaccine. (FDA, 2024b)
Are there Paragraph IV challenges to ENGERIX-B?
A conventional Paragraph IV challenge is not the expected pathway for competition against ENGERIX-B because Paragraph IV certifications apply to patents listed in the Orange Book for approved drug products. ENGERIX-B is a biologic vaccine licensed under the BLA pathway.
Potential competitors would generally pursue one of the following routes:
- Independent BLA approval for a recombinant hepatitis B vaccine.
- An applicable biosimilar or interchangeable pathway, if the product and regulatory framework permit it.
- Approval of a different hepatitis B vaccine using a distinct antigen, adjuvant, schedule, or combination approach.
- Inclusion of hepatitis B antigen in a combination vaccine.
For practical market analysis, the relevant risk is product approval and procurement displacement, not an ANDA-based generic launch.
Is ENGERIX-B exposed to biosimilar risk?
ENGERIX-B has limited conventional biosimilar risk. Vaccines are not exposed to biosimilar competition in the same way as therapeutic monoclonal antibodies such as Humira, Stelara, or Keytruda. Competing hepatitis B vaccines typically enter as independently developed vaccines or as products with distinct formulations and clinical packages.
The more immediate competitive risks are:
- Heplisav-B’s two-dose adult schedule.
- Recombivax HB’s established market presence.
- Pediatric combination vaccines.
- New adjuvanted or higher-immunogenicity products.
- Government tenders that prioritize lowest cost per completed series.
- Manufacturing disruptions that shift contracts among suppliers.
What formulation patents protect ENGERIX-B?
The core commercial value of ENGERIX-B is unlikely to depend on an active, product-specific formulation patent. Vaccine protection often rests on a combination of manufacturing knowledge, cell-bank controls, antigen purification, adjuvant handling, analytical methods, stability data, and regulatory history.
The product uses recombinant hepatitis B surface antigen with an aluminum-containing adjuvant system. The relevant barriers include:
- Control of recombinant yeast expression systems.
- Antigen purification and conformational integrity.
- Consistent particle and antigen characteristics.
- Sterility assurance and viral or microbial control.
- Stability through distribution and storage.
- Lot-to-lot comparability.
- Validation of manufacturing processes.
- Regulatory documentation accumulated over decades.
These barriers can delay entry even when basic composition patents are no longer active. They also make reliable supply a material competitive advantage in government and institutional markets.
What method-of-use patents protect ENGERIX-B?
Method-of-use patents are not expected to be a major source of current exclusivity for ENGERIX-B. The product is used for broad immunization against hepatitis B infection, and its main indications are established preventive uses rather than narrow patented treatment methods.
Commercial differentiation is more likely to come from:
- Age-specific schedules.
- High-risk population dosing.
- Combination-vaccine positioning.
- Interchangeability within immunization programs.
- Completion rates for multi-dose series.
- Institutional vaccination protocols.
What patent litigation affects ENGERIX-B?
No major current patent-litigation thesis is evident from the product’s mature regulatory history and non-Orange Book status. Competition is more likely to arise through regulatory approvals, contract awards, supply constraints, and commercial positioning than through patent infringement litigation.
Potential disputes could still involve manufacturing processes, confidential know-how, employee mobility, trade secrets, or vaccine supply agreements. Those risks differ from a conventional branded-drug patent case and are less likely to produce a predictable litigation-driven launch date.
What generic launch risks exist for ENGERIX-B?
The risk of a conventional generic launch is low because ENGERIX-B is a biologic vaccine, not a chemically synthesized small molecule. The more realistic scenario is gradual share erosion from independently approved vaccines and combination products.
Likely launch scenarios
| Scenario |
Probability profile |
Commercial effect |
| Direct generic substitution |
Low |
Not the normal regulatory pathway |
| New recombinant hepatitis B vaccine |
Ongoing market possibility |
Price and volume pressure |
| Adult share shift to Heplisav-B |
Material in the U.S. |
Reduces standalone adult demand |
| Pediatric substitution by combination products |
Ongoing |
Limits growth in standalone pediatric doses |
| Government tender loss |
Episodic but material |
Can cause abrupt regional volume declines |
| Supply disruption |
Two-sided risk |
May cause share loss or temporary demand capture |
| New global entrant |
More relevant outside the U.S. |
Increases tender competition |
What is the geographic coverage of ENGERIX-B?
ENGERIX-B has broad international presence through GSK’s global vaccine operations. The commercial model differs by region:
- The United States is driven by CDC recommendations, private insurance, occupational health, pharmacies, and public procurement.
- Europe relies more heavily on national immunization schedules and country-specific tendering.
- Emerging markets are influenced by UNICEF, Gavi-supported programs, national procurement, and local manufacturing.
- Travel and expatriate markets support private-sector demand for adult hepatitis A and B combination vaccination.
- Pediatric markets favor combination products where national programs seek to reduce injection counts.
Geographic revenue is not separately disclosed for ENGERIX-B. Product demand is therefore best assessed through vaccine procurement trends and GSK’s overall geographic vaccine performance rather than through a reported product-level sales series.
How strong is the ENGERIX-B commercial and patent estate?
The patent estate is weak as a source of current exclusivity because the product is mature and its original protection is historical. The commercial estate remains stronger than the patent estate because it includes regulatory experience, manufacturing capability, product familiarity, supply relationships, and established use in immunization programs.
| Dimension |
Assessment |
| Patent exclusivity |
Low current significance |
| Regulatory barrier |
High |
| Manufacturing barrier |
High |
| Brand recognition |
Strong among healthcare purchasers |
| Adult competitive position |
Moderate, pressured by Heplisav-B |
| Pediatric position |
Strong but exposed to combination products |
| Pricing power |
Limited in public tenders |
| Revenue durability |
Moderate to strong |
| Growth potential |
Low to moderate |
| Litigation protection |
Limited |
| Supply-chain value |
High |
Key Takeaways
- ENGERIX-B is a mature recombinant hepatitis B vaccine marketed by GSK.
- GSK does not disclose ENGERIX-B revenue separately, so standalone financial performance cannot be derived from public filings.
- The product’s financial profile is likely stable and volume-driven, with limited pricing power.
- Heplisav-B is the most important differentiated adult competitor in the U.S.
- Recombivax HB remains a direct legacy competitor.
- Pediatric combination vaccines can displace standalone ENGERIX-B doses.
- ENGERIX-B does not face a conventional Orange Book patent cliff or Paragraph IV challenge.
- Biosimilar risk is limited; independent vaccine approvals and tender competition are more important.
- Current commercial barriers are manufacturing, regulatory, quality, supply reliability, and procurement access.
- GSK’s financial exposure is likely modest relative to its larger vaccine products, particularly Shingrix and Arexvy.
Frequently Asked Questions
Is ENGERIX-B still commercially important?
Yes. Its growth rate is mature, but it remains relevant in pediatric immunization, adult vaccination, occupational health, dialysis, travel medicine, and government procurement.
Is ENGERIX-B interchangeable with Heplisav-B?
Interchangeability depends on applicable vaccination guidance, product labeling, patient age, dose schedule, and clinical circumstances. The products are not commercially identical because they use different schedules and adjuvant approaches.
Does ENGERIX-B have biosimilar competition?
Not in the conventional therapeutic-biologic sense. Competitive hepatitis B vaccines generally enter through independent vaccine development and approval rather than biosimilar substitution.
Can a generic manufacturer launch ENGERIX-B after patent expiry?
A conventional ANDA generic launch is not the expected route. A competing manufacturer would generally need an applicable biologics or vaccine approval and its own validated manufacturing process.
What is the biggest commercial threat to ENGERIX-B?
The largest threats are adult share migration to two-dose products, pediatric substitution by combination vaccines, aggressive public-sector tender pricing, and competition from other recombinant hepatitis B vaccines.
References
-
Centers for Disease Control and Prevention. (2024). Hepatitis B vaccination: Information for healthcare providers. https://www.cdc.gov/hepatitis-b/hcp/vaccine-considerations/
-
GSK plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/annual-report/
-
U.S. Food and Drug Administration. (2024a). ENGERIX-B prescribing information. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
